清肺口服液联合喜炎平注射液治疗小儿博卡病毒肺炎的临床研究

目的观察清肺口服液联合喜炎平注射液治疗小儿博卡病毒肺炎的临床疗效。方法将59例博卡病毒肺炎患儿随机分为治疗组与对照组,治疗组采用清肺口服液联合喜炎平注射液治疗,对照组给予氨溴特罗口服液和利巴韦林注射液治疗,观察两组患儿的综合疗效,及治疗前后主症积分、次症积分和症状总积分变化情况。结果治疗组综合疗效优于对照组(P0.05);两组治疗后主症积分、次症积分、症状总积分均较治疗前降低(P0.05);在治疗后主症积分、次症积分和症状总积分下降方面,治疗组优于对照组(P0.05)。结论清肺口服液联合喜炎平注射液治疗小儿博卡病毒肺炎疗效确切。

Clinical research of Qingfei Oral Liqulid and Xiyanping Injection in treatment of children with human bocavirus pneumonia

Objective To observe the clinical effect of Qingfei Oral Liqulid and Xiyanping Injection in the treatment of children with human bocavirus pneumonia. Methods Children with human bocavirus pneumonia (59 cases) were randomly divided into treatment group and control group. The cases in the treatment group were treated with Qingfei Oral Liqulid and Xiyanping Injection, and those in the control group were given Ambroxol and Clenbuterol oral solution and Ribavirin injection. The comprehensive efficacy, before and after treatment of primary symptoms scores, secondary symptoms scores, and total scores of symptoms were observed. Results The treatment group had superior comprehensive efficacy over the control group (P<0.05). Both groups had reduced scores for primary symptoms and secondary symptoms and total scores for symptoms after treatment (P<0.05). The decreases in the scores for primary symptoms and secondary symptoms and the total scores for symptoms after treatment were larger in the treatment group than those in the control group (P<0.05). Conclusion Qingfei Oral Liqulid and Xiyanping Injection had definitive efficacy in the treatment of human bocavirus pneumonia in children.